[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349446-105":59,"doc-detail-349446-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","moving-beyond-the-female-only-paradigm-arguments-for-accelerating-the-global-gender-neutral-human-papillomavirus-vaccination","Moving Beyond the Female-Only Paradigm - Arguments for Accelerating the Global Gender-Neutral Human Papillomavirus Vaccination","","Since its adoption into public health programmes in 2006, the Human Papillomavirus (HPV) vaccine has reduced cervical cancer, yet substantial HPV burden remains linked to non-cervical cancers and conditions that are often overlooked due to a historically gendered HPV narrative. Although gender-neutral vaccination (GNV) is expanding, global endorsement—especially in low- and middle-income countries (LMICs)—is delayed. This perspective argues for accelerated universal gender-neutral HPV vaccination by addressing non-cervical cancer burden, advancing gender justice, and strengthening population-wide herd immunity despite shifting funding and healthcare disparities, while improving programme resilience where female coverage is insufficient.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/moving-beyond-the-female-only-paradigm-arguments-for-accelerating-the-global-gender-neutral-human-papillomavirus-vaccination/349446/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/moving-beyond-the-female-only-paradigm-arguments-for-accelerating-the-global-gender-neutral-human-papillomavirus-vaccination/349446.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main argument of the perspective paper?","Question",{"text":112,"@type":113},"It advocates accelerating a global shift from female-only HPV vaccination to universal, gender-neutral HPV vaccination to address neglected non-cervical outcomes and support population-wide protection.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why do the authors say the female-only approach can create problems?",{"text":117,"@type":113},"They argue it can exacerbate stigma and inequity, and it fails to address broader health outcomes across society, even if it improves some specific outcomes for protected groups.",{"name":119,"@type":110,"acceptedAnswer":120},"What benefits does gender-neutral vaccination offer according to the paper?",{"text":121,"@type":113},"It helps address rising non-cervical cancer burden, promotes gender justice for vulnerable groups, and strengthens herd immunity amid funding and healthcare disparities, particularly in LMICs.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349446,1790503357,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Moving Beyond the Female-Only Paradigm: Arguments for Accelerating the Global Gender-Neutral Human Papillomavirus Vaccination  \nCancer Control Volume 33: 1–7 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10732748261466385](DOI: 10.1177/10732748261466385)  \n[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nAaron Remkes1,2, Tarik Gheit3 , Guillermo Z. Martínez-Pérez4 , and Daniela Fusco, PhD1,2  \nAbstract  \nSince its adoption into public health programmes in 2006, the Human Papillomavirus (HPV) vaccine has proven its powerful effect in preventing cervical cancer, the most prevalent HPV-associated cancer. Nevertheless, a considerable burden of HPV infection is associated with non-cervical cancers and conditions that, due to a historically gendered narrative around HPV vaccination, are still partially neglected in most preventive agendas. Gender-neutral vaccination (GNV) programmes have been steadily adopted in an increasing number of countries, but global endorsement of this strategy is still being delayed, especially in low-and middle-income countries (LMICs). In this perspective paper, we advocate for an accelerated global shift from female-only to universal, gender-neutral HPV vaccination. This perspective analyses how a GNV strategy addresses the rising burden of non-cervical cancers, promotes gender justice for vulnerabilised groups, and strengthens population-wide herd immunity amidst shifting global funding and healthcare disparities, particularly in LMICs. Further, a gender-neutral approach could also strengthen programme resilience in settings where female vaccination coverage remains far below the elimination targets. The case of HPV vaccination shows that women-only public health interventions can further exacerbate the stigmatisation of women in society and, rather than improving women’s health, amplify inequity. We believe that the experience with the HPV vaccine can play a significant role in demonstrating that women-specific vaccination programmes can have unintended consequences: whilst they may improve specific health outcomes, they simultaneously cause social harm to thesex groups they intend to protect, thereby failing to address broader health outcomes across the global society asa whole.  \nKeywords  \nHPV vaccination, gender neutral vaccination, gender, equity, vaccination strategies  \nReceived: 1 April 2026; Revised: 29 May 2026; Accepted: 22 June 2026  \n1Research Group: Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany 2German Center for Infection Research (DZIF), Hamburg-Borstel-Lübeck-Riems, Germany  \n3Early Detection, Prevention, and Infections, International Agency for Research on Cancer (IARC), Lyon, France 4Epicentre, Médecins Sans Frontières, Genève, Switzerland  \nCorresponding author:  \nDaniela Fusco, PhD, Research Group: Implementation Research, Bernhard Nocht Institute for Tropical Medicine; German Center for Infection Research (DZIF), Hamburg-Borstel-Lübeck-Riems, Bernhard Nocht Strasse 74, Hamburg 20359, Germany.  \nEmail: [fusco@bnitm.de](fusco@bnitm.de)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons  \nAttribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages ([https://us.sagepub.com/en-us/nam/open-access-at-sage](https://us.sagepub.com/en-us/nam/open-access-at-sage)).  \nBackground  \nSince its initial regulatory approval in 2006, the human papillomavirus (HPV) vaccine has been fully integrated into national immunisation programmes of 161 out of 194 World Health Organization (WHO) member states. 1 The vaccine and its further d","cbCaikPjbw4bHH2l","https://ap.wps.com/l/cbCaikPjbw4bHH2l","pdf",1143096,"English","# Abstract\n## Background\n## Rationale for gender-neutral vaccination\n## Implementation and equity considerations","[{\"question\":\"What is the main argument of the perspective paper?\",\"answer\":\"It advocates accelerating a global shift from female-only HPV vaccination to universal, gender-neutral HPV vaccination to address neglected non-cervical outcomes and support population-wide protection.\"},{\"question\":\"Why do the authors say the female-only approach can create problems?\",\"answer\":\"They argue it can exacerbate stigma and inequity, and it fails to address broader health outcomes across society, even if it improves some specific outcomes for protected groups.\"},{\"question\":\"What benefits does gender-neutral vaccination offer according to the paper?\",\"answer\":\"It helps address rising non-cervical cancer burden, promotes gender justice for vulnerable groups, and strengthens herd immunity amid funding and healthcare disparities, particularly in LMICs.\"}]","Moving Beyond the Female-Only Paradigm - Arguments for Accelerating the Global Gender-Neutral Human Papillomavirus Vaccination | PDF",1790083346,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd8fe0cfd750bdd0207be99903d32d6e.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee99910e40e444d592997af2880fdad1.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a72fe6893ae56ff7b5b8a67daad2982d.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e38f4a1f62e3be669dc556e9cd57473c.webp",980,1306]